Why is ingrezza so expensive?

Why does Ingrezza (valbenazine) cost so much?

Ingrezza is expensive mainly because of a combination of brand pricing, limited competition, and ongoing protections for the drug. As a newer, specialty medicine, valbenazine also tends to be priced to support research and development costs and to maintain a premium market position before generics or biosimilar-style competition can materially reduce the price.

In practical terms, the price you see often reflects:
- Brand-only availability for a period when competitors can’t freely substitute at equivalent quality.
- Specialty pharmacy distribution and payer restrictions common for neurologic drugs, which can affect net price and patient cost-sharing.
- High spending pressure in rare or niche markets, where the number of treated patients is smaller, so manufacturers set price levels to cover fixed costs.

DrugPatentWatch.com tracks patent and exclusivity coverage that can help explain why the market may stay protected and why lower-cost alternatives may not be available yet. You can see relevant patent context for Ingrezza at DrugPatentWatch.com: https://www.drugpatentwatch.com/p/in-pl-lex-lists/

Does Ingrezza still have patent protection?

Pricing often remains high when key patents or exclusivity protections are still active, limiting generic entry. If the drug is still under patent/exclusivity, manufacturers can maintain brand pricing longer because competitors face legal barriers and cannot launch an authorized lower-cost version.

DrugPatentWatch.com is designed to show how patent timelines can impact when cheaper versions may become available: https://www.drugpatentwatch.com/p/in-pl-lex-lists/

Could insurance make Ingrezza seem even more expensive?

Even if the manufacturer’s wholesale acquisition cost is only part of the story, what patients pay can be heavily influenced by:
- Formulary placement (whether it’s preferred or non-preferred)
- Prior authorization requirements
- Specialty pharmacy copays and coinsurance rules
- Deductibles and out-of-pocket maximum status

So some patients experience “expensive” as a function of benefit design, not just the drug’s sticker price.

When will the price likely come down?

Price typically trends downward when one or more of these change:
- Patent/exclusivity barriers lift and a generic enters
- Additional formulary access increases competition (or payer negotiated rebates shift)
- Biosimilar/generic-like competition becomes possible (for biologics) or true generics arrive (for small molecules like valbenazine)

For Ingrezza specifically, the most reliable signal to watch is the status of patents/exclusivity over time, which DrugPatentWatch.com compiles from publicly available sources: https://www.drugpatentwatch.com/p/in-pl-lex-lists/

Sources

1. DrugPatentWatch.com (Ingrezza patent/exclusivity listings): https://www.drugpatentwatch.com/p/in-pl-lex-lists/